Published in J Antimicrob Chemother on September 01, 1982
Effect of broad-spectrum parenteral antibiotics on composition of intestinal microflora of humans. Antimicrob Agents Chemother (1987) 1.47
Effect of moxalactam on human fecal microflora. Antimicrob Agents Chemother (1986) 1.19
Effects of treatment with antimicrobial agents on the human colonic microflora. Ther Clin Risk Manag (2008) 1.13
Pharmacokinetic properties of the cephalosporins. Drugs (1987) 1.13
Side effects of cephalosporins. Drugs (1987) 1.11
Modulation of the intestinal flora of mice by parenteral treatment with broad-spectrum cephalosporins. Antimicrob Agents Chemother (1991) 1.09
Interleukin-6, gamma interferon, and tumor necrosis factor receptors in typhoid fever related to outcome of antimicrobial therapy. Antimicrob Agents Chemother (1993) 1.01
Mathematical model of plasmid-mediated resistance to ceftiofur in commensal enteric Escherichia coli of cattle. PLoS One (2012) 0.99
Methods to evaluate biliary excretion of drugs in humans: an updated review. Mol Pharm (2006) 0.98
Crossover study of the pharmacokinetics of ceftriaxone administered intravenously or intramuscularly to healthy volunteers. Antimicrob Agents Chemother (1983) 0.97
Comparative efficacies of single intravenous doses of ceftriaxone and ampicillin for shigellosis in a placebo-controlled trial. Antimicrob Agents Chemother (1986) 0.91
Impact of injectable cephalosporins on the gastrointestinal microflora: observations in healthy volunteers and hospitalized patients. Infection (1985) 0.86
Effect of a single dose of cefotaxime or ceftriaxone on human faecal flora. A double-blind study. Drugs (1988) 0.85
Influence of plasma exchange pheresis on plasma elimination of ceftriaxone. Antimicrob Agents Chemother (1990) 0.83
Characteristics of ceftriaxone binding to immunoglobulin G and potential clinical significance. Antimicrob Agents Chemother (1991) 0.82
Quantitative measurement of biliary excretion and of gall bladder concentration of drugs under physiological conditions in man. Gut (1989) 0.80
Pharmacokinetics of ceftriaxone in patients with typhoid fever. Antimicrob Agents Chemother (1994) 0.79
Pharmacokinetic interaction between itraconazole and ceftriaxone in Yucatan miniature pigs. Antimicrob Agents Chemother (1997) 0.79
Influence of temocillin on human bowel flora. Drugs (1985) 0.79
Effects of aztreonam on fecal flora and on vitamin K metabolism. Antimicrob Agents Chemother (1990) 0.79
Ampicillin in Combination with Ceftaroline, Cefepime, or Ceftriaxone Demonstrates Equivalent Activities in a High-Inoculum Enterococcus faecalis Infection Model. Antimicrob Agents Chemother (2016) 0.77
Ecological Effect of Ceftaroline-Avibactam on the Normal Human Intestinal Microbiota. Antimicrob Agents Chemother (2015) 0.76
Modelling dynamics of plasmid-gene mediated antimicrobial resistance in enteric bacteria using stochastic differential equations. Sci Rep (2013) 0.76
No effect of probenecid on the renal and biliary clearances of digoxin in man. Br J Clin Pharmacol (1991) 0.75
Toxic and adverse reactions encountered with new beta-lactam antibiotics. Bull N Y Acad Med (1984) 0.75
A Novel Tightly Regulated Gene Expression System for the Human Intestinal Symbiont Bacteroides thetaiotaomicron. Front Microbiol (2016) 0.75
BDDCS, the Rule of 5 and drugability. Adv Drug Deliv Rev (2016) 0.75
Reversible Ceftriaxone-Induced Pseudolithiasis in an Adult Patient with Maintenance Hemodialysis. Case Rep Nephrol Dial (2015) 0.75
Evaluation of five test-kits-API, AuxoTab, Enterotube, PathoTec and R-B-for identification of Enterobacteriaceae. Med Microbiol Immunol (1974) 8.61
Formation of beta-lactamase in Bacteroides fragilis: cell-bound and extracellular activity. Antimicrob Agents Chemother (1976) 4.64
Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis (2001) 4.17
Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J Intern Med (2006) 2.70
Antibiotic susceptibility of anaerobic bacteria with special reference to Bacteroides fragilis. Scand J Infect Dis Suppl (1979) 2.66
Disposition of chloroquine in man after single intravenous and oral doses. Br J Clin Pharmacol (1983) 2.59
Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia. Lancet (1990) 2.55
Determination of chloroquine and its desethyl metabolite in plasma, red blood cells and urine by liquid chromatography. J Chromatogr (1982) 2.40
Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study. J Antimicrob Chemother (2001) 2.35
Evaluation of two test-kits--API and Oxi Ferm tube--for identification of oxidative-fermentative Gram-negative rods. Med Microbiol Immunol (1977) 2.31
Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans. Circulation (1999) 2.27
Antimicrobial agents and Clostridium difficile in acute enteric disease: epidemiological data from Sweden, 1980-1982. J Infect Dis (1985) 2.16
Factors contributing to resistance to beta-lactam antibiotics in Bacteroides fragilis. Antimicrob Agents Chemother (1979) 2.15
Immunochemical fingerprinting of Clostridium difficile strains isolated from an outbreak of antibiotic-associated colitis and diarrhoea. J Med Microbiol (1984) 2.07
Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. N Engl J Med (1990) 2.06
Effect of vancomycin on intestinal flora of patients who previously received antimicrobial therapy. Clin Infect Dis (1997) 2.02
Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXRbeta-deficient mice. J Clin Invest (2001) 1.95
Antibacterial activity of new beta-lactam antibiotics on cefoxitin-resistant strains of Bacteroides fragilis. J Antimicrob Chemother (1980) 1.95
Obesity and disturbed lipoprotein profile in estrogen receptor-alpha-deficient male mice. Biochem Biophys Res Commun (2000) 1.94
Prophylactic administration of penicillins for endocarditis does not reduce the incidence of postextraction bacteremia. Clin Infect Dis (1993) 1.92
A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin. Clin Pharmacol Ther (1985) 1.87
Plasma protein binding of tricyclic anti-depressants in man. Biochem Pharmacol (1969) 1.86
Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function. N Engl J Med (1971) 1.76
In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia. Antimicrob Agents Chemother (2001) 1.74
Plasma protein binding of basic drugs. II. Importance of alpha 1-acid glycoprotein for interindividual variation. Clin Pharmacol Ther (1977) 1.70
Rapid grouping of streptococci by immunoelectroosmophoresis. Med Microbiol Immunol (1974) 1.67
Development of the faecal anaerobic microflora after caesarean section and treatment with antibiotics in newborn infants. Infection (1987) 1.66
Factors controlling the bacterial colonization of the intestine in breastfed infants. Acta Paediatr Suppl (1999) 1.62
Hepatic uptake of bile acids in man. Fasting and postprandial concentrations of individual bile acids in portal venous and systemic blood serum. J Clin Invest (1982) 1.61
Plasma protein binding of basic drugs. I. Selective displacement from alpha 1-acid glycoprotein by tris(2-butoxyethyl) phosphate. Clin Pharmacol Ther (1977) 1.61
Effect of phenoxymethylpenicillin and clindamycin on the oral, throat and faecal microflora of man. Scand J Infect Dis (1979) 1.61
Biochemical characterization and in vitro determination of antibiotic susceptibility of clinical isolates of Bacteroides fragilis. Scand J Infect Dis (1974) 1.57
The composition of the faecal microflora in breastfed and bottle fed infants from birth to eight weeks. Acta Paediatr Scand (1985) 1.56
Susceptibility to beta-lactam antibiotics and production of beta-lactamase in Bacteroides fragilis. Med Microbiol Immunol (1977) 1.55
Antibiotic susceptibility testing of anaerobic bacteria by the standardized disc diffusion method with special reference to bacteroides fragilis. Scand J Infect Dis (1975) 1.54
Aspects on antibacterial treatment of anaerobic infections. Scand J Infect Dis Suppl (1982) 1.53
Comparative effects of omeprazole, amoxycillin plus metronidazole versus omeprazole, clarithromycin plus metronidazole on the oral, gastric and intestinal microflora in Helicobacter pylori-infected patients. J Antimicrob Chemother (1999) 1.52
Beta-lactamase-producing Bacteroides species in the oral cavity in relation to penicillin therapy. J Antimicrob Chemother (1981) 1.52
Bile acid kinetics and biliary lipid composition in cystic fibrosis. J Hepatol (1996) 1.51
Correlation between serum levels of some cholesterol precursors and activity of HMG-CoA reductase in human liver. J Lipid Res (1987) 1.50
Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med (1993) 1.50
Risk for fatal statin-induced rhabdomyolysis as a consequence of misinterpretation of 'evidence-based medicine'. J Intern Med (2005) 1.48
Biliary lipid composition during treatment with different hypolipidaemic drugs. Eur J Clin Invest (1979) 1.48
In vitro effect of metronidazole and tinidazole on anaerobic bacteria. Med Microbiol Immunol (1974) 1.47
Probiotics and gastrointestinal diseases. J Intern Med (2005) 1.47
Chronic meningitis caused by a penicillin-sensitive microorganism? Lancet (1983) 1.46
Characterization of three different beta-lactamases from the Bacteroides fragilis group. Antimicrob Agents Chemother (1980) 1.45
Pharmacokinetics and tissue penetration of tazobactam and piperacillin in patients undergoing colorectal surgery. Antimicrob Agents Chemother (1992) 1.45
Kinetics of diphenylhydantoin in uraemic patients: consequences of decreased plasma protein binding. Eur J Clin Pharmacol (1974) 1.44
Secretion and composition of bile after human liver transplantation: studies on the effects of cyclosporine and tacrolimus. Transplantation (1997) 1.43
Two-fold interindividual variation in plasma protein binding of phenytoin in patients with epilepsy. Clin Pharmacokinet (1977) 1.41
Prolonged and profound acid inhibition is crucial in Helicobacter pylori treatment with a proton pump inhibitor combined with amoxicillin. Scand J Gastroenterol (1998) 1.40
Evidence for the absorption of bile acids in the proximal small intestine of normo- and hyperlipidaemic subjects. Gut (1976) 1.39
Ecological effects of linezolid versus amoxicillin/clavulanic acid on the normal intestinal microflora. Scand J Infect Dis (2001) 1.37
Resistance to beta-lactam antibiotics in Bacteroides species. J Antimicrob Chemother (1981) 1.36
Synergistic effect of combinations of sulfamethoxazole, trimethoprim, and colistin against Pseudomonas maltophilia and Pseudomonas cepacia. Antimicrob Agents Chemother (1974) 1.35
Effects of cholestyramine and chenodeoxycholic acid on the metabolism of endogenous triglyceride in hyperlipoproteinemia. J Lipid Res (1978) 1.35
Impact of antimicrobial agents on the gastrointestinal microflora and the risk of infections. Am J Med (1984) 1.34
On the question of dose-dependent chloroquine elimination of a single oral dose. Clin Pharmacol Ther (1983) 1.34
Type III hyperlipoproteinemia: recent insights into the genetic defect of familial dysbetalipoproteinemia. Adv Intern Med (1984) 1.34
Importance of growth hormone for the induction of hepatic low density lipoprotein receptors. Proc Natl Acad Sci U S A (1992) 1.34
The normal human anaerobic microflora. Scand J Infect Dis Suppl (1982) 1.33
Detection and quantitation by lysis-filtration of bacteremia after different oral surgical procedures. J Clin Microbiol (1990) 1.32
Distinct ribotypes and rates of antimicrobial drug resistance in Clostridium difficile from Shanghai and Stockholm. Clin Microbiol Infect (2009) 1.31
Pharmacokinetics of indomethacin. Clin Pharmacol Ther (1975) 1.31
In-vitro susceptibility of anaerobic bacteria to GAR-936, a new glycylcycline. Clin Microbiol Infect (2000) 1.31
In vitro sensitivity of isolates of Pseudomonas aeruginosa to carbenicillin, gentamicin, tobramycin, and some other antibiotics. Scand J Infect Dis (1974) 1.29
Influence of age on secretion of cholesterol and synthesis of bile acids by the liver. N Engl J Med (1985) 1.28
Fecal bacterial microflora of newborn infants during intensive care management and treatment with five antibiotic regimens. Pediatr Infect Dis (1986) 1.28
Numerical taxonomy and laboratory identification of Actinomyces and Arachnia and some related bacteria. J Gen Microbiol (1975) 1.27
Comparative effects of moxifloxacin and clarithromycin on the normal intestinal microflora. Scand J Infect Dis (2000) 1.27
Serological studies of Actinomyces israelii by crossed immunoelectrophoresis: taxonomic and diagnostic applications. Infect Immun (1975) 1.27
Effect of cefoperazone on faecal flora. J Antimicrob Chemother (1983) 1.26
Isolation of beta-lactamase-producing Bacteroides strains associated with clinical failures with penicillin treatment of human orofacial infections. Arch Oral Biol (1980) 1.26
Comparative in vitro activity of the new oral penem ALP-201 against aerobic and anaerobic bacteria. Eur J Clin Microbiol Infect Dis (1989) 1.26
Lipoprotein profiles in plasma and interstitial fluid analyzed with an automated gel-filtration system. Eur J Clin Invest (2006) 1.26
Autosomal recessive hypercholesterolaemia: normalization of plasma LDL cholesterol by ezetimibe in combination with statin treatment. J Intern Med (2004) 1.26
Norfloxacin binds to human fecal material. Antimicrob Agents Chemother (1988) 1.25
The role of Bacteroides fragilis in the pathogenesis of acute appendicitis. Acta Chir Scand (1982) 1.25
Decreased plasma protein binding of phenytoin in patients on valproic acid. Br J Clin Pharmacol (1979) 1.25
Pharmacokinetics of budesonide in children with asthma. Eur J Clin Pharmacol (1987) 1.25
Clinical pharmacology and the provision of drug information. Eur J Clin Pharmacol (1992) 1.25
Antibiotic susceptibility of Clostridium species isolated from human infections. Scand J Infect Dis (1975) 1.25
Characterization of three Aeromonas and nine pseudomonas species by extracellular enzymes and haemolysins. Med Microbiol Immunol (1975) 1.22
Thyroid hormone receptor beta-deficient mice show complete loss of the normal cholesterol 7alpha-hydroxylase (CYP7A) response to thyroid hormone but display enhanced resistance to dietary cholesterol. Mol Endocrinol (2000) 1.22
Regulation of hepatic lipoprotein receptors in the dog. Rapid regulation of apolipoprotein B,E receptors, but not of apolipoprotein E receptors, by intestinal lipoproteins and bile acids. J Clin Invest (1983) 1.22
European surveillance study on the antibiotic susceptibility of Propionibacterium acnes. Clin Microbiol Infect (2005) 1.22
Determination of chloroquine and its desethyl metabolite in whole blood: an application for samples collected in capillary tubes and dried on filter paper. Ther Drug Monit (1985) 1.21
Dose-dependent absorption of amoxycillin and bacampicillin. Clin Pharmacol Ther (1985) 1.21
Pharmacokinetics and biological effects of nortriptyline in man. Acta Pharmacol Toxicol (Copenh) (1971) 1.21
Characterization of chloroquine plasma protein binding in man. Br J Clin Pharmacol (1983) 1.21
Pharmacokinetics of ciprofloxacin and effect of repeated dosage on salivary and fecal microflora. Antimicrob Agents Chemother (1986) 1.20
Individual bile acids in portal venous and systemic blood serum of fasting man. Gastroenterology (1977) 1.20
Imipenem/cilastatin in the treatment of intraabdominal infections: a review of worldwide experience. Rev Infect Dis (1985) 1.20
Serum antibody response to Clostridium difficile toxins in patients with Clostridium difficile diarrhoea. Infection (1985) 1.18
Pronounced variation in bile acid synthesis in humans is related to gender, hypertriglyceridaemia and circulating levels of fibroblast growth factor 19. J Intern Med (2011) 1.17
Production of phospholipase C (alpha-toxin), haemolysins and lethal toxins by Clostridium perfringens types A to D. J Gen Microbiol (1976) 1.17
Comparative in vitro activity of BAY 12-8039 and five other antimicrobial agents against anaerobic bacteria. Eur J Clin Microbiol Infect Dis (1998) 1.16